Effect of long-term immunotherapy on relapse rates in patients with MOGAD

Takeaway

  • Maintenance immunotherapy may reduce recurrent central nervous system (CNS) demyelinating attacks in patients with myelin oligodendrocyte glycoprotein (MOG) immunoglobulin G (IgG) associated disorder (MOGAD).

Why this matters

  • MOGAD is a CNS demyelinating disease characterized by frequent relapses, with approximately half of all patients experiencing a recurrent demyelinating attack, most commonly optic neuritis.

  • Research suggests that long-term immunosuppressant therapy may reduce the frequency of recurrent demyelinating attacks in patients with MOGAD but large studies on long-term therapy for this condition are lacking and an optimal treatment strategy is still unknown.

  • This study examined the efficacy of maintenance immunotherapy for the prevention of recurrent demyelinating attacks.